| Literature DB >> 24758906 |
Yinghua Song1, Caiqing Zhang1, Zhixin Cao2, Jiawen Xu2, Lingcheng Wang3, Xiaoyan Lin2.
Abstract
BACKGROUND ANDEntities:
Mesh:
Substances:
Year: 2014 PMID: 24758906 PMCID: PMC6000016 DOI: 10.3779/j.issn.1009-3419.2014.04.05
Source DB: PubMed Journal: Zhongguo Fei Ai Za Zhi ISSN: 1009-3419
E-cadherin、β-catenin和vimentin在肺SCC肿瘤中央细胞及ITF细胞的表达
Comparetion between E-cadherin, β-catenin and vimentin expression of ITF cells and tumor central cells
| Group | E-cadherin | Vimentin | ||||||||||||
| N: negative; L: low expression; H: high expression; ITF: invasive tumor front. SCC: squamous cell carcinoma. | ||||||||||||||
| N | L | H | N | L | H | N | L | H | ||||||
| Non-ITF | 14 | 20 | 70 | 0.008 | 7 | 9 | 88 | 0.013 | 80 | 16 | 8 | 0.008 | ||
| ITF | 26 | 30 | 48 | 13 | 21 | 70 | 60 | 24 | 20 | |||||
1EMT相关蛋白在肺SCC中的表达。E-cadherin在肺SCC组织中的表达情况(A),在中央肿瘤组织胞膜强阳性(B),而ITF细胞中为阴性(C);β-catenin在肺SCC组织中的表达情况(D),显示在肿瘤中央细胞胞膜和胞浆阳性(E),而ITF组织中为阴性(F);vimentin在肺SCC组织中的表达(G),显示肿瘤中央细胞为阴性表达(H),而在ITF组织中高表达(I)(HE染色,A、D和G ×100倍;B、C、E、F、H、I×400倍)
EMT protein expression was examined by immunohistochemistry in lung SCC. Expression of E-cadherin in lung SCC (A): E-cadherin was strong positive membranous staining (B), but negative was found in ITF cells (C); Expression of β-catenin in lung SCC (D), β-catenin was membranous or cytoplasmic positive staining (E), but negative in ITF cells (F); Expression of vimentin in lung SCC (G): vimentin was cytoplasmic positive staining (H), but negative in ITF cells (I). (A, D, H, ×100; B, C, E, F, H, I, ×400). EMT: epithelial-mesenchymal transition
E-cadherin、β-catenin和vimentin三者在SCC ITF细胞的表达与各种临床病理特征的关系
Relationship between E-cadherin, β-catenin and vimentin expression levels of ITF cells and clinical variables of SCC
| Group | E-cadherin | vimentin | ||||||||||
|
| ||||||||||||
| L | H | L | H | L | H | |||||||
| Gender | 0.60 | 0.11 | 0.76 | |||||||||
| Male | 72 | 34 | 38 | 20 | 52 | 45 | 27 | |||||
| Female | 32 | 22 | 10 | 14 | 18 | 19 | 13 | |||||
| Age (yr) | 0.82 | 0.49 | 0.87 | |||||||||
| ≤50 | 38 | 21 | 17 | 14 | 24 | 23 | 15 | |||||
| > 50 | 66 | 35 | 31 | 20 | 46 | 41 | 25 | |||||
| Tumor location | 0.85 | 0.79 | 0.94 | |||||||||
| Central | 81 | 44 | 37 | 27 | 54 | 50 | 31 | |||||
| Peripheral | 23 | 12 | 11 | 7 | 16 | 14 | 9 | |||||
| Tumor size (cm) | 0.14 | 0.07 | 0.45 | |||||||||
| ≤3 | 62 | 37 | 25 | 16 | 46 | 40 | 22 | |||||
| > 3 | 42 | 19 | 23 | 18 | 24 | 24 | 18 | |||||
| Histological differentiation | 0.07 | 0.40 | 0.53 | |||||||||
| Well | 27 | 15 | 12 | 9 | 18 | 19 | 8 | |||||
| Moderate | 54 | 25 | 29 | 15 | 39 | 31 | 23 | |||||
| Poor | 23 | 16 | 7 | 10 | 13 | 14 | 9 | |||||
| Invasion pattern | 0.01* | 0.52 | 0.02* | |||||||||
| 1 | 18 | 6 | 12 | 6 | 12 | 13 | 5 | |||||
| 2 | 22 | 9 | 13 | 10 | 12 | 17 | 5 | |||||
| 3 | 35 | 18 | 17 | 10 | 25 | 23 | 12 | |||||
| 4 | 29 | 23 | 6 | 8 | 21 | 11 | 18 | |||||
| TNM stage | 0.44 | 0.30 | 0.12 | |||||||||
| Ⅰ | 41 | 24 | 17 | 11 | 30 | 29 | 12 | |||||
| Ⅱ/Ⅲ | 63 | 32 | 31 | 23 | 40 | 35 | 28 | |||||
| Lymph node status | 0.04* | 0.02* | 0.03* | |||||||||
| N (+) | 59 | 37 | 22 | 25 | 34 | 31 | 28 | |||||
| N0 | 45 | 19 | 26 | 9 | 36 | 33 | 12 | |||||
| Recurence | 0.04* | 0.04* | 0.01* | |||||||||
| Yes | 29 | 20 | 9 | 14 | 15 | 12 | 17 | |||||
| No | 75 | 36 | 39 | 20 | 55 | 52 | 23 | |||||
2ITF细胞中EMT表型与患者预后的关系。A:E-cadherin;B:vimentin
Survival curve by expression of E-cadherin and vimentin in lung SCC. A: E-cadherin; B: vimentin